Get the Stockscreener App
2.77
1.77%
-0.05
After Hours:
2.78
0.010
+0.36%
Sagimet Biosciences Inc stock is traded at $2.77, with a volume of 342.04K.
It is down -1.77% in the last 24 hours and down -10.06% over the past month.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).
See More
Previous Close:
$2.82
Open:
$2.82
24h Volume:
342.04K
Relative Volume:
0.85
Market Cap:
$87.25M
Revenue:
-
Net Income/Loss:
$-27.92M
P/E Ratio:
-2.4018
EPS:
-1.1533
Net Cash Flow:
$-22.89M
1W Performance:
-3.15%
1M Performance:
-10.06%
6M Performance:
-48.89%
1Y Performance:
-68.52%
1-Day Range:
$2.66
$2.90
1-Week Range:
$2.66
$3.01
52-Week Range:
$2.13
$20.71
Sagimet Biosciences Inc Stock (SGMT) Company Profile
Name
Sagimet Biosciences Inc
Sector
Industry
Phone
(650) 561-8600
Address
155 BOVET RD., SUITE 303, SAN MATEO
Sagimet Biosciences Inc Stock (SGMT) Latest News
Victory Capital Management Inc. Purchases 25,480 Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
Examining the Potential Price Growth of Surgery Partners Inc (SGRY) - Knox Daily
Esperion Therapeutics exec sells over $4,600 in stock - Investing.com
SEGRO (LON:SGRO) Reaches New 1-Year Low at $8.89 - Defense World
Surgery Partners Inc (SGRY) stock on the rise: An overview - US Post News
Bokf Na Purchases Shares of 11,905 Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World
BofA Securities Downgrades Esperion Therapeutics Inc. (ESPR) to an Underperform from a Neutral - Knox Daily
Surgery Partners Inc (SGRY) is looking forward to a strong quarter - SETE News
Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 5% - MarketBeat
Los Angeles Capital Management LLC Lowers Holdings in Surgery Partners, Inc. (NASDAQ:SGRY) - Defense World
Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit - GlobeNewswire
Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit - StockTitan
There is no way Sagimet Biosciences Inc (SGMT) can keep these numbers up - SETE News
Sagimet Biosciences Inc (SGMT) Stock: A Year of Market Movement, Down and Up - The InvestChronicle
What to expect from SGMT’s earnings report this quarter? - US Post News
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences - GlobeNewswire
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences - StockTitan
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences - Marketscreener.com
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences - Yahoo Finance
Should investors be concerned about Sagimet Biosciences Inc (SGMT)? - US Post News
Top investors say Sagimet Biosciences Inc (SGMT) ticks everything they need - SETE News
Sagimet Biosciences maintains buy rating on strong trial data - Investing.com
Price T Rowe Associates Inc. MD Takes Position in Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
Sagimet Biosciences Inc. to Post Q3 2024 Earnings of ($0.52) Per Share, HC Wainwright Forecasts (NASDAQ:SGMT) - Defense World
Q3 2024 Earnings Forecast for Sagimet Biosciences Inc. (NASDAQ:SGMT) Issued By HC Wainwright - MarketBeat
Sagimet Biosciences Inc. (NASDAQ:SGMT) Forecasted to Earn Q3 2024 Earnings of ($0.43) Per Share - Defense World
Sagimet Biosciences initiates $75 million equity offering - Investing.com India
Sagimet Biosciences (NASDAQ:SGMT) Announces Quarterly Earnings Results - Defense World
ORG Partners LLC Purchases New Position in Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
HC Wainwright Reiterates “Buy” Rating for Sagimet Biosciences (NASDAQ:SGMT) - Defense World
Sagimet Biosciences (NASDAQ:SGMT) PT Lowered to $32.00 - Defense World
Vanguard Group Inc. Purchases 894,319 Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT) - MarketBeat
Vanguard Group Inc. Grows Stock Position in Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
Financial Review: Lipella Pharmaceuticals (NASDAQ:LIPO) vs. Sagimet Biosciences (NASDAQ:SGMT) - Defense World
Sagimet Biosciences initiates $75 million equity offering By Investing.com - Investing.com Australia
Sagimet Biosciences initiates $75 million equity offering - Investing.com
Sagimet Biosciences (NASDAQ:SGMT) Posts Quarterly Earnings Results, Beats Estimates By $0.09 EPS - MarketBeat
Sagimet Biosciences (NASDAQ:SGMT) PT Lowered to $32.00 - MarketBeat
Sagimet Biosciences (NASDAQ:SGMT) Rating Reiterated by HC Wainwright - MarketBeat
Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewswire
Sagimet Biosciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
What's Going On With Sagimet Biosciences Stock On Thursday? - MSN
Sagimet Biosciences Inc. (SGMT): Should You Buy This New Penny Stock Now? - Insider Monkey
Sagimet Biosciences Inc. (SGMT): Should You Buy This New Penny Stock Now? - Yahoo Finance
10 Best New Penny Stocks To Buy Now - Insider Monkey
20,000 Shares in Sagimet Biosciences Inc. (NASDAQ:SGMT) Purchased by DekaBank Deutsche Girozentrale - Defense World
American International Group Inc. Grows Stock Holdings in Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
O Shaughnessy Asset Management LLC Invests $72,000 in Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
Sagimet Biosciences expands board, appoints two new directors - Investing.com India
Sagimet Biosciences expands board, appoints two new directors - Investing.com
Sagimet Biosciences Inc. Announces Appointment of Board of Directors - Marketscreener.com
Sagimet Biosciences Inc Stock (SGMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):